Holen Sie sich die Stockscreener-App
6.10
0.00%
0.00
Handel nachbörslich:
6.14
0.04
+0.66%
Atea Pharmaceuticals Inc Aktie (AVIR) Neueste Nachrichten
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month HighHere's Why - MarketBeat
Atea Pharma presents data on compounds for hepatitis E - bioworld.com
Atea Pharmaceuticals (AVIR) Price Target Raised by Evercore ISI - GuruFocus
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript - Insider Monkey
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks - AOL.com
Atea Pharmaceuticals’ Earnings Call Flags Pivotal 2026 - TipRanks
Can Atea Pharmaceuticals Inc stock double in the next year2025 Winners & Losers & Consistent Income Trade Ideas - baoquankhu1.vn
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
Atea Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Atea Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Atea Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
AVIR: Phase III HCV trials near completion, HEV pipeline expanded, and cash runway extends through 2027 - TradingView
Atea Pharma (AVIR) Earnings Call Transcript - AOL.com
Earnings call transcript: Atea Pharmaceuticals Q4 2025 sees stock rise despite EPS miss - Investing.com
AVIR: Phase 3 HCV trials near completion, with robust cash and new HEV candidate advancing - TradingView
Atea Pharmaceuticals (NASDAQ:AVIR) Posts Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
Atea Pharmaceuticals 10-K: $0 Revenue, $(158.3)M Net Loss - TradingView
Atea Pharmaceuticals (Nasdaq: AVIR) narrows 2025 loss and advances HCV, HEV pipeline - Stock Titan
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Yahoo Finance
Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings - Benzinga
Risk Off: Can Atea Pharmaceuticals Inc navigate macro headwinds2025 Key Highlights & AI Driven Price Predictions - baoquankhu1.vn
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction - AOL.com
What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally - AOL.com
AVIR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 - The Manila Times
Atea Pharmaceuticals to Host Fourth Quarter and Full Year - GlobeNewswire
AVIR SEC FilingsAtea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday - Defense World
AVIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Atea Pharmaceuticals presents preclinical results of AT-587 - marketscreener.com
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026 - GlobeNewswire
No approved hepatitis E drugs: experimental pill shows powerful lab results - Stock Titan
BML Capital Management LLC Cuts Holdings in Atea Pharmaceuticals, Inc. $AVIR - Defense World
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million - AOL.com
Why Did Compass Pathways Stock Rocket Higher Today? - AOL.com
Is Atea Pharmaceuticals Inc. stock recession proofJuly 2025 Retail & Low Risk Entry Point Tips - mfd.ru
Published on: 2026-02-08 21:54:48 - baoquankhu1.vn
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 2%Here's What Happened - MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 2%Time to Sell? - MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 2% – Here’s What Happened - Defense World
Bayer says its experimental blood thinner cuts risk of stroke recurrence by 26% - AOL.com
Street Watch: Is Atea Pharmaceuticals Inc attractive for institutional investorsIndex Update & Safe Capital Growth Stock Tips - baoquankhu1.vn
Aug Closing: Is Atea Pharmaceuticals Inc still a buy after recent gains2025 Historical Comparison & Risk Controlled Swing Alerts - baoquankhu1.vn
Aug Sectors: Will BIIB benefit from sector rotationJuly 2025 Final Week & Risk Managed Investment Entry Signals - baoquankhu1.vn
Will Atea Pharmaceuticals Inc. face regulatory challengesDividend Hike & Weekly Breakout Opportunity Watchlist - mfd.ru
Risk Hedge: Can Atea Pharmaceuticals Inc stock double in the next yearJuly 2025 Retail & Technical Pattern Based Buy Signals - baoquankhu1.vn
Update Report: Is Atea Pharmaceuticals Inc stock undervalued right now2025 Key Highlights & Accurate Intraday Trade Tips - baoquankhu1.vn
Aug EndMonth: Can The AZEK Company Inc stock double in the next yearJuly 2025 WrapUp & Real-Time Market Trend Scan - baoquankhu1.vn
Institutional Investors Are Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Biggest Bettors and Were Rewarded After Last Week's US$56m Market Cap Gain - 富途牛牛
Can Atea Pharmaceuticals Inc expand into new marketsEarnings Recap Report & Risk Managed Trade Strategies - baoquankhu1.vn
Spotlight On Atea Pharmaceuticals And 2 Other Noteworthy Penny Stocks - Yahoo Finance
Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan Conference - MarketBeat
Is Atea Pharmaceuticals Inc. still a buy after recent gainsBlue Chip Stock Analysis & Daily Tips From Top Market Analysts - bollywoodhelpline.com
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens - Pharmaceutical Technology
Dip Buying: Can Atea Pharmaceuticals Inc stock double in the next year2025 Bull vs Bear & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Is Apellis Pharmaceuticals’ FDA Win Just the Beginning? - AOL.com
Buyout Rumor: Is Atea Pharmaceuticals Inc a momentum stockTrend Reversal & Expert Curated Trade Setups - baoquankhu1.vn
Wall Street Recap: Will Atea Pharmaceuticals Inc face regulatory challengesTrade Volume Report & Long-Term Investment Growth Plans - baoquankhu1.vn
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):